Form 8-K

8-K — Spectral AI, Inc.

Accession: 0001213900-26-100119

Filed: 2026-09-15

Period: 2026-09-14

CIK: 0001833498

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — ea0305581-8k_spectral.htm (Primary)

EX-99.1 — SPECTRAL AI INVESTOR PRESENTATION, DATED SEPTEMBER 14, 2026 (ea030558101ex99-1.htm)

GRAPHIC (ea030558101_ex99-1img1.jpg)

GRAPHIC (ea030558101_ex99-1img2.jpg)

GRAPHIC (ea030558101_ex99-1img3.jpg)

GRAPHIC (ea030558101_ex99-1img4.jpg)

GRAPHIC (ea030558101_ex99-1img5.jpg)

GRAPHIC (ea030558101_ex99-1img6.jpg)

GRAPHIC (ea030558101_ex99-1img7.jpg)

GRAPHIC (ea030558101_ex99-1img8.jpg)

GRAPHIC (ea030558101_ex99-1img9.jpg)

GRAPHIC (ea030558101_ex99-1img10.jpg)

GRAPHIC (ea030558101_ex99-1img11.jpg)

GRAPHIC (ea030558101_ex99-1img12.jpg)

GRAPHIC (ea030558101_ex99-1img13.jpg)

GRAPHIC (ea030558101_ex99-1img14.jpg)

GRAPHIC (ea030558101_ex99-1img15.jpg)

GRAPHIC (ea030558101_ex99-1img16.jpg)

GRAPHIC (ea030558101_ex99-1img17.jpg)

GRAPHIC (ea030558101_ex99-1img18.jpg)

GRAPHIC (ea030558101_ex99-1img19.jpg)

GRAPHIC (ea030558101_ex99-1img20.jpg)

GRAPHIC (ea030558101_ex99-1img21.jpg)

GRAPHIC (ea030558101_ex99-1img22.jpg)

GRAPHIC (ea030558101_ex99-1img23.jpg)

GRAPHIC (ea030558101_ex99-1img24.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0305581-8k_spectral.htm · Sequence: 1

false

0001833498

2026-09-14

0001833498

MDAI:CommonStockParValue0.0001PerShareMember

2026-09-14

0001833498

MDAI:RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf2.75PerShareMember

2026-09-14

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(D) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): September 14, 2026

SPECTRAL

AI, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-40058

85-3987148

(State

or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S.

Employer

Identification No.)

2515

McKinney Avenue, Suite 1000

Dallas,

Texas

75201

(Address

of principal executive offices)

(Zip

Code)

(972)

499-4934

(Registrant’s

telephone number, including area code)

Not

Applicable

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of

the following provisions:

☐

Written communication pursuant

to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications

pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencements communications

pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbols

Name

of each exchange on which registered

Common

Stock, par value $0.0001 per share

MDAI

The

Nasdaq Stock Market LLC

Redeemable

Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

MDAIW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01. Regulation FD Disclosure.

September 14, 2026, the Company posted an investor presentation to its website at www.spectral-ai.com (the “Investor Presentation”).

A copy of the Investor Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The Company will use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations

to investors, analysts and others.

The

information in this Item 7.01 to this Current Report on Form 8-K, and in Exhibit 99.1 furnished herewith, shall not be deemed

to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing

under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such

a filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

99.1

Spectral AI Investor Presentation, dated September 14, 2026.

104

Cover Page Interactive

Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report to be signed on its behalf

by the undersigned hereunto duly authorized.

Dated:

September 15, 2026

SPECTRAL AI, INC.

By:

/s/ Vincent

S. Capone

Name:

Vincent S. Capone

Title:

Chief Executive Officer

EX-99.1 — SPECTRAL AI INVESTOR PRESENTATION, DATED SEPTEMBER 14, 2026

EX-99.1

Filename: ea030558101ex99-1.htm · Sequence: 2

Exhibit

99.1

Predictive Wound Healing AI + Multispectral Imaging = Faster, More Accurate Treatment Decisions in Healthcare Nasdaq: MDAI September 2026 1

Revolutionizing Wound Care Delivering on Commitments 13-year track record of meeting milestones validated by $250M+ non-dilutive government funding. • Proof of concept • Clinical validation • Product validation Prioritizing growth opportunities in profitable markets, positioning ourselves for near-term commercial success. • UKCA Approval • FDA De Novo 2013-2026 DeepView is a single platform supporting multiple indications. Extensive portfolio of patents, trade secrets and "truthed" images are a significant barrier to competition. DeepView System enables healthcare providers to make more informed treatment choices. In a matter of seconds during the initial patient visit, DeepView predicts if the wound will heal or not, with remarkable accuracy. ©2026 Spectral AI 2

Where We Stand Today Cleared, Funded, and Entering Commercial Launch May 21, 2026 FDA De Novo classification granted Authorized to commence commercial sales in the United States. $250M+ Developed on non-dilutive capital Government funding since 2013 carried the platform to FDA clearance 30 systems First deployments are subsidized BARDA funding supports procurement for 30 US burn and trauma centers $150M Contracted revenue base Project BioShield contract with BARDA; $86.6M committed to date.¹ 3-year term Recurring revenue on every placement Device sale plus a multi-year SaaS contract Expansion Beyond US UK, Australia and Gulf Cooperation Countries Evaluation in 5 UK sites and 3 Australian sites 1. Contract values per the Company's Form 10-Q for the quarter ended June 30, 2026. Obligation of contract value not yet committed is at BARDA's election and is not assured. ©2026 Spectral AI 3

We See What Clinicians Cannot Burn wound depth and healing potential are difficult to assess visually, leading to delayed treatment, unnecessary excisions, and variable outcomes. The Result Provides same-day, objective assessment of wound areas that are unlikely to heal within 21 days, supporting clinical judgment and driving earlier and more accurate treatment decisions. The Problem Current workflow relies on subjective clinician judgment and invasive diagnostics. The Solution: DeepView® System Non-invasive, cart-based imaging platform combines multispectral imaging + proprietary AI + ground truth data to predict burn wound healing potential. ©2026 Spectral AI Our Diagnostic Advantage 4

DeepView Imaging Patented proprietary multi- spectral imaging data acquisition in milliseconds Capturing injured tissue spectral signature Data extraction Extraction of AI model features, such as tissue characteristics that determine health Combined with patient health matrix data AI model trained and tested against a proprietary clinical database of more than 340+bn clinically validated data points AI algorithm integrates image and clinical data for model training AI model building Accurate and immediate binary wound healing prediction in seconds Predicting wound healing in 21 days at initial presentation Healing prediction Non-healing output Decision: surgery or advanced wound care products Healing output Decision: Routine care At Initial Presentation - Image to Wound Prediction in Seconds ©2026 Spectral AI Our Technology 5

Competitive Advantage Measured Against Clinical Judgment ©2026 Spectral AI Sensitivity Detecting non-healing tissue DeepView 88% Burn physicians 42% DeepView Dice score Accuracy of wound segmentation 0.39 DeepView detected 88% of non-healing burns, while unaided clinical assessment missed 58% at initial presentation. DeepView more than doubles non-healing detection rates. Reproducibility of assessment of wound segmentation from Dice Score shows a consistency not found in clinician evaluation. A category with no predicate FDA granted De Novo classification because no legally marketed device was substantially equivalent. DeepView® is now itself the predicate. Confirmed in a multi-reader study Clinicians reading the same cases were more accurate overall, and detected more non-healing tissue, when using DeepView than when reading unaided — with no loss of specificity. Performance as authorized in the DeepView® System labeling. Sensitivity is a detection metric; Dice is a segmentation measure. Physician figures reflect clinical judgment annotation. Specificity data is available on request. 0.69 Burn physicians 6

Competitive Moat Data, Algorithm and Patents ©2026 Spectral AI The paired image and outcome data, the AI algorithm and the patent portfolio — backed by thirteen years and over $250.0 million of non-dilutive government funding — provide a strong competitive moat. Truthed burn image bank Every image paired with a confirmed outcome — histopathological biopsy or 21- day healing, adjudicated by an expert panel of burn surgeons. 340+bn pixels of burn wound image data Patents and trade secrets across 9 patent classes Protection spanning multispectral acquisition, feature extraction and the AI architecture, built over more than a decade of development. 13 years of protected development A broad patent and trademark portfolio 13 issued and allowed U.S. patents with 5 applications pending; 21 issued and allowed international patents with 23 foreign and international applications pending. 34 / 47 patents and trademarks issued Pixel count per the Company's De Novo announcement. Ground truth established by histopathological biopsy or 21-day healing assessment. Patent and trademark counts per the Company's Form 10-K filed March 21, 2025; totals comprise 34 patents and 28 patent applications, 47 trademarks and 11 trademark applications. 7

Expanding Diagnostic Accuracy Diagnostic Accuracy Gets Made Where the Expertise Is Missing ©2026 Spectral AI ~5,000 U.S. emergency departments with no burn-specialized training 132 U.S. burn centers, staffed by roughly 250 burn surgeons1 21 days Time required to confirm by observation which burns heal Both directions of error are costly Under-triage A burn that will not heal on its own is managed conservatively. Surgery is delayed, length of stay extends, patient outcome is worse, hospital costs expanded. Over-triage A burn that would have healed is sent to surgery. The patient undergoes an avoidable operation, length of stay extends, patient outcome is worse, hospital costs expanded. 1. Burn center count per the American Burn Association registry. 8

Clinician • Informed treatment decisions • Increased efficiency Care Facility • Uniformed clinical decisions • Equality of care • Improved efficiency • Government digital initiatives Patient • Reduced treatment time for patients and caregiver burden • Reduced infection and treatment complications • Reduced pain and suffering Payers • Eliminated unnecessary payments • Objective and validated treatment support REDUCING LENGTH OF STAY IMPROVED PATIENT OUTCOMES DECREASED COSTS PER INPATIENT IMPROVED EXPERIENCE INNOVATION JUSTIFICATION ©2026 Spectral AI Systemwide Benefits Improving Health and Cost Outcomes for All 9

Regulatory Update De Novo Classification Granted: May 21, 2026 ©2026 Spectral AI FDA granted De Novo classification as novel, new technology with no substantial equivalent Eligibility Reserved for devices that are first of their kind, with no suitable predicate on the market. Regulatory classification Reclassifies the device from Class III to a lower class, with special controls. Initial Procurement An initial 30 DeepView systems are subsidized under the BARDA award. Commercial Expansion Initial U.S. Market and expansion to U.K., Australia and Gulf Coast Cooperative countries. What the authorization establishes First De Novo authorization for burn wound healing prediction Only AI system cleared to predict burn healing on day one Basis A classification other devices must now file against De Novo classification granted May 21, 2026. BARDA system count per the Company's contract; pipeline targets are estimates and do not represent contracted placements. 10

Optimizing Coding, Coverage & Payment Site of Service: Inpatient üHealthy DRG payments exist for severe burn patients (up to ~$205k) üEvaluating opportunities to further increase hospital payment to reflect value of DeepView® Site of Service: Outpatient/ASCs üCMS has proposed assigning software as a medical service (SaMS) to New Tech APCs üDeepView® may be considered SaMS allowing for separate additional payment üSpectral has submitted request to CMS to recognize DeepView® as a SaMS and to assign it to NT-APC 1523 which has a payment rate of $2,750. CPT Code: Physician Services üCategory III Code Already Attained üCMS proposed rule would enable local MACs the ability to price CPT 0972T ASC In-patient Out-patient Physician Hospital DRG APC CPT Reimbursement Strategy ©2026 Spectral AI 11

Commercial Model Two Revenue Lines and a Staged Adoption Path ©2026 Spectral AI Device placement Revenue on delivery Capital purchase, lease, or outcomes-linked. Software and services Recurring annual revenue Three-year minimum. Compounds with every placement. Service and support1 What drives revenue timing Existing clinical site Fastest New install, no committee Capital review, then procurement Committee plus AI/IT review Slowest — 6 to 12 months Clinical exception Fast Annual service and support Preventive maintenance, helpdesk and warranty, on-site visits, a dedicated account manager and staff training. 1. Service scope shown is illustrative. Contract structure, term and pricing are subject to negotiation and no pricing has been finalized. 12

Path to Profitability How the Addressable Base Expands ©2026 Spectral AI The addressable base widens on one platform Available now ~130 ABA-verified burn centers BARDA subsidizes the first 30 device placements › Same indication, wider footprint 236 U.S. facilities treating burns Trauma centers and non-verified centers that still see burn volume › Where patients actually present ~5,000 U.S. emergency departments No burn-specialized training; requires site-of-service expansion And margin improves as it grows Mix Product revenue replaces cost-reimbursed development revenue as the contract scope narrows. Recurrence Annual contracts persist for as long as a unit is installed and accumulate with every placement. Leverage The commercial and support organization scales far more slowly than the installed base it serves. Burn center count per the American Burn Association; facilities treating burns and emergency department counts are estimates derived from registry and claims data. Indications listed are under evaluation and have not been selected; expansion beyond the cleared burn indication requires additional clinical, regulatory and commercial work and is not assured. Illustrative of the operating model; contains no projection of future revenue, expenses, results of operations or the timing of profitability. 13

©2026 Spectral AI One Imaging Platform, Multiple Indications Potential Indications Amputation Critical Limb Ischemia Diabetic Foot Ulcers Plastic Surgery Miniaturized Mobile Home Healthcare Burn Wound Global market $3.7B11 Anticipate selling 2026 2026 DeepView SnapShot® M | Handheld Military and Commercial INDICATIONS Total grant awarded $7.1M for miniaturization of technology Our Platform 14

Financial Position Balance Sheet and Results of Operations ©2026 Spectral AI Balance sheet June 30, 2026 Cash $14.0M Total assets $19.4M Notes payable $14.9M Total liabilities $31.5M Stockholders' deficit $(12.1)M Results of operations FY2024 FY2025 H1 2026 Revenue $29.6M $19.7M $7.5M Gross profit $13.3M $8.9M $3.1M Operating expenses $19.9M $17.5M $9.4M Operating loss $(6.6)M $(8.6)M $(6.3)M Revenue tracked the development program that delivered FDA authorization — which is complete $54.9M Late-stage development through FDA authorization Base period — complete June 2026 $31.7M Devices and follow-on development Exercised March 2026 $63.4M Options not yet exercised Exercisable at the government's discretion Beyond the contract Device sales and recurring service, post-authorization Company cost share A portion of follow-on development is Company-funded Balance sheet at June 30, 2026; results of operations for the years ended December 31, 2024 and 2025 and the six months ended June 30, 2026, per the Company's Forms 10-K and 10-Q. Phase bar drawn to scale against the $150.0M PBS BARDA contract. Options are exercisable at the government's discretion and are not assured. 15 $150.0M total BARDA contract — non-dilutive

Capital Deployment Funding the Commercial Ramp Beyond BARDA ©2026 Spectral AI Proceeds fund the commercial ramp and the expansion of the cleared indication — the two things that convert FDA authorization into recurring revenue. 1 Commercialization ramp Building the sales team and device inventory needed to convert FDA clearance into placements. 2 International device rollout Extending placements beyond the United States, supported by the UKCA marking obtained in February 2024. 3 Label expansion Broadening the range of burn diagnostics to hands, head and feet in the US and UK markets. 4 Additional indication research Evaluating and selecting the next clinical indication for the platform, and the work required to support it. Allocation is indicative and subject to change. Statements regarding the use of proceeds are forward-looking, are not projections of results, and are subject to the risks described in the Company's filings. 16

Progress and Catalysts What We Have Delivered and What Comes Next ©2026 Spectral AI Delivered February 2024 UKCA marking obtained 2025 Pivotal enrollment complete across 16 sites March 2026 BARDA accelerated $31.7M of contract funding May 2026 FDA De Novo classification granted June 2026 Handheld prototype delivered to MTEC July 2026 Chief Commercial Officer appointed Ahead1 By year end 2026 First commercial sales targeted Late 2026 MTEC Phase 3 selection expected November 2026 CMS final rule on Category III code 0972T Through June 2027 Planned deployment of up to 30 systems with BARDA subsidy June 2027 Label Expansion for heads, hands & feet, UKCA Expanded approval, Initial Overseas sales 1. Reflects milestones previously disclosed publicly. Forward-looking statements are not guarantees of future performance and timing may change. 2027-2028 Expanded US and Overseas sales 17

Leadership Built for Commercial Execution ©2026 Spectral AI Vincent Capone Chief Executive Officer Joined March 2022, prior CFO and General Counsel. Former President of a technology/life sciences private equity fund, partner at Reed Smith. David McGuire Chief Financial Officer Joined May 2026. Formerly Chief Accounting Officer of Solo Brands and Deputy CFO of EZCORP. 14 years at EY, CPA. Stan Micek Chief Operating Officer SVP for Business Development and Strategy at MiMedx, after leadership roles at Ohio State and Abbott Laboratories. Darcy Bajko Chief Commercial Officer Joined July 2026 from MediView XR, where she launched three FDA-cleared imaging platforms. Previously Smith+Nephew and Integra LifeSciences. Allison Kumar Head of Global Regulatory & Clinical Affairs A decade at FDA CDRH as lead reviewer and senior program manager for medical countermeasures. Inter-agency work across FDA, CDC, BARDA and DoD. 18

Board of Directors Clinical, Financial and Commercial Oversight ©2026 Spectral AI Dr. J. Michael DiMaio Chairman Dr. J. Michael DiMaio, founder and large shareholder with over 30 years of experience in cardiothoracic surgery and specializes in heart valve replacement and lung transplantation. Richard Cotton Director Richard Cotton has a wealth of experience in senior financial roles in life sciences and other sectors, including broadcast and photographic, automotive, filtration and metals. Deepak Sadagopan Director Deepak Sadagopan serves as Business Lead at Risant Health, where he is accountable for expanding adoption of the value-based platform. Martin Mellish Director Founding director of Aspen Advisory Services since 1994, a London-based private office investing across North America, Europe and Asia. Marion Snyder Director Senior Director of Strategic Accounts at Shockwave Medical, leading corporate strategy for corporate and government accounts. 19

Appendix Reference List ©2026 Spectral AI 1. Data from Spectral MD's IRB approved Proof of Concept Clinical Study 2. Pixel data per Spectral MD clinical studies. 3. Anyanwu JA, Cindass R. Burn Debridement, Grafting, and Reconstruction. [Updated 2023 May 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551717/ 4. Huson HB, Phelan HA, G'Sell DJ, Smith S, Carter JE. If Seeing Was Believing A Retrospective Analysis of Potential Reduced Treatment Delays with a Novel Burn Wound Assessment Device. JBCR 2021;(42)S117-18 5. Definitive Healthcare 2019 Private Pay and CMS pay of inpatient versus outpatient DRG codes 6. Definitive Healthcare 2019 Cost and Claims Data from Medicare and Private Payer Estimates 7. American Burn Association, National Burn Repository and burn incidence statistics. 8. DeepView® System performance data as authorized in FDA labeling, De Novo classification granted May 21, 2026. 9. Centers for Medicare & Medicaid Services, CY2027 Hospital Outpatient Prospective Payment System proposed rule (CMS-1850-P), July 7, 2026. 10. American Medical Association Current Procedural Terminology (CPT®) 21 11. Grand View Research, Global Burn Care Market Size & Share Report, 2021–2028. Figure reflects the global burn care market, not the Company's addressable market.

Forward Looking Statements Certain statements made in this presentation are "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company's strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the "Risk Factors" sections of the Company's filings with the US Securities and Exchange Commission, including the Company's Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. ©2026 Spectral AI Legal 22

Additional Information and Where to Find It This presentation is provided for informational purposes only. Spectral AI investors and stockholders will be able to obtain copies of any documents filed with the SEC, without charge, at the SEC's website at www.sec.gov. No Offer or Solicitation This presentation and the information contained herein do not constitute (i) (a) a solicitation of a proxy, consent or authorization with respect to any securities or (b) an offer to sell or the solicitation of an offer to buy any security, commodity or instrument or related derivative, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction or (ii) an offer or commitment to lend, syndicate or arrange a financing, underwrite or purchase or act as an agent or advisor or in any other capacity with respect to any transaction, or commit capital, or to participate in any trading strategies. No offer of securities in the United States or to or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act) shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. Investors should consult with their counsel as to the applicable requirements for a purchaser to avail itself of any exemption under the Securities Act. Trademarks All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this presentation are for identification purposes only. Use of these names, trademarks and brands does not imply endorsement. Disclaimers ©2026 Spectral AI Legal 23

GRAPHIC

Filename: ea030558101_ex99-1img1.jpg · Sequence: 3

Binary file (389806 bytes)

Download ea030558101_ex99-1img1.jpg

GRAPHIC

Filename: ea030558101_ex99-1img2.jpg · Sequence: 4

Binary file (404164 bytes)

Download ea030558101_ex99-1img2.jpg

GRAPHIC

Filename: ea030558101_ex99-1img3.jpg · Sequence: 5

Binary file (343151 bytes)

Download ea030558101_ex99-1img3.jpg

GRAPHIC

Filename: ea030558101_ex99-1img4.jpg · Sequence: 6

Binary file (441507 bytes)

Download ea030558101_ex99-1img4.jpg

GRAPHIC

Filename: ea030558101_ex99-1img5.jpg · Sequence: 7

Binary file (400502 bytes)

Download ea030558101_ex99-1img5.jpg

GRAPHIC

Filename: ea030558101_ex99-1img6.jpg · Sequence: 8

Binary file (356869 bytes)

Download ea030558101_ex99-1img6.jpg

GRAPHIC

Filename: ea030558101_ex99-1img7.jpg · Sequence: 9

Binary file (346477 bytes)

Download ea030558101_ex99-1img7.jpg

GRAPHIC

Filename: ea030558101_ex99-1img8.jpg · Sequence: 10

Binary file (370297 bytes)

Download ea030558101_ex99-1img8.jpg

GRAPHIC

Filename: ea030558101_ex99-1img9.jpg · Sequence: 11

Binary file (464287 bytes)

Download ea030558101_ex99-1img9.jpg

GRAPHIC

Filename: ea030558101_ex99-1img10.jpg · Sequence: 12

Binary file (374773 bytes)

Download ea030558101_ex99-1img10.jpg

GRAPHIC

Filename: ea030558101_ex99-1img11.jpg · Sequence: 13

Binary file (318645 bytes)

Download ea030558101_ex99-1img11.jpg

GRAPHIC

Filename: ea030558101_ex99-1img12.jpg · Sequence: 14

Binary file (301515 bytes)

Download ea030558101_ex99-1img12.jpg

GRAPHIC

Filename: ea030558101_ex99-1img13.jpg · Sequence: 15

Binary file (329497 bytes)

Download ea030558101_ex99-1img13.jpg

GRAPHIC

Filename: ea030558101_ex99-1img14.jpg · Sequence: 16

Binary file (306809 bytes)

Download ea030558101_ex99-1img14.jpg

GRAPHIC

Filename: ea030558101_ex99-1img15.jpg · Sequence: 17

Binary file (374146 bytes)

Download ea030558101_ex99-1img15.jpg

GRAPHIC

Filename: ea030558101_ex99-1img16.jpg · Sequence: 18

Binary file (305275 bytes)

Download ea030558101_ex99-1img16.jpg

GRAPHIC

Filename: ea030558101_ex99-1img17.jpg · Sequence: 19

Binary file (318057 bytes)

Download ea030558101_ex99-1img17.jpg

GRAPHIC

Filename: ea030558101_ex99-1img18.jpg · Sequence: 20

Binary file (315423 bytes)

Download ea030558101_ex99-1img18.jpg

GRAPHIC

Filename: ea030558101_ex99-1img19.jpg · Sequence: 21

Binary file (319910 bytes)

Download ea030558101_ex99-1img19.jpg

GRAPHIC

Filename: ea030558101_ex99-1img20.jpg · Sequence: 22

Binary file (76908 bytes)

Download ea030558101_ex99-1img20.jpg

GRAPHIC

Filename: ea030558101_ex99-1img21.jpg · Sequence: 23

Binary file (217378 bytes)

Download ea030558101_ex99-1img21.jpg

GRAPHIC

Filename: ea030558101_ex99-1img22.jpg · Sequence: 24

Binary file (282563 bytes)

Download ea030558101_ex99-1img22.jpg

GRAPHIC

Filename: ea030558101_ex99-1img23.jpg · Sequence: 25

Binary file (292413 bytes)

Download ea030558101_ex99-1img23.jpg

GRAPHIC

Filename: ea030558101_ex99-1img24.jpg · Sequence: 26

Binary file (369194 bytes)

Download ea030558101_ex99-1img24.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 32

v3.26.3

Cover

Sep. 14, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 14, 2026

Entity File Number

001-40058

Entity Registrant Name

SPECTRAL

AI, INC.

Entity Central Index Key

0001833498

Entity Tax Identification Number

85-3987148

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2515

McKinney Avenue

Entity Address, Address Line Two

Suite 1000

Entity Address, City or Town

Dallas

Entity Address, State or Province

Entity Address, Postal Zip Code

75201

City Area Code

(972)

Local Phone Number

499-4934

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock, par value $0.0001 per share

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

MDAI

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

Title of 12(b) Security

Redeemable

Warrants, each whole warrant exercisable for one share of Common Stock, at an exercise price of $2.75 per share

Trading Symbol

MDAIW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=MDAI_CommonStockParValue0.0001PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=MDAI_RedeemableWarrantsEachWholeWarrantExercisableForOneShareOfCommonStockAtExercisePriceOf2.75PerShareMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: